The American Cancer Society (ACS) has updated its guideline for human papilloma virus (HPV) vaccination. New recommendations are for healthcare providers to routinely offer the HPV vaccine series to boys and girls between ages 9 and 12.
Les Yonemoto, MD MBAACS Updates HPV Vaccination Recommendations to Start at Age 9. #Prevent #Cancer #GynOnc
Treatment with olanzapine (Zyprexa) can greatly reduce nausea and vomiting in people with advanced cancer, a small clinical trial has shown. The study’s leaders believe that olanzapine may fill a need for patients with advanced cancer whose nausea...
FDA has approved olaparib (Lynparza) and rucaparib (Rubraca) to treat some men with metastatic prostate cancer. The drugs, both PARP inhibitors, are approved to treat men whose cancers have stopped responding to hormone treatments and have specific...
Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.
Les Yonemoto, MD MBAFDA approves immunotherapy combination for treatment of patients with unresectable or metastatic #Hepatocellular carcinoma #Cancer
Incidence of regional and distant-stage prostate cancer has continued to increase among men aged 50 years and older in the United States, according to results of a retrospective study published in Journal of the National Cancer Institute. “We don’t...
Les Yonemoto, MD MBAAdvanced prostate cancer cases have increased among older men, as early-stage disease cases have declined, study indicates. #ProstateCancer #CAP #RadOnc
Background The impact of cardiovascular risk burden on cognitive trajectories and brain structure changes remains unclear.
Objectives This study aimed to examine whether cardiovascular risk burden assessed by the Framingham General Cardiovascular...
Les Yonemoto, MD MBAPreventing heart disease may be protective against cognitive decline.
Journal of the American College of Cardiology
Clovis Oncology Inc said on Friday the U.S. Food and Drug Administration has approved its drug Rubraca for the treatment of adult patients with metastatic castration-resistant prostate cancer, whose tumors have a genetic mutation.
Les Yonemoto, MD MBAFDA approves rucaparib for patients with prostate cancer tumors with BRCA mutation #Cancer #CAP #ProstateCancer #Research